Topical immunotherapy clears precancerous skin lesions and reduces cancer risk

CHICAGO — Subcutaneous amivantamab (Rybrevant) was non-inferior to IV amivantamab for pre-treated patients with refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC), with the suggestion

In certain patients with mild-to-moderate acute ischemic stroke, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (Plavix) reduced early neurologic deterioration better than aspirin alone,

Share this article Caption: Experts recommend collaboration between regulatory agencies to increase market access to essential medicines. Credit: Vitalii Stock via Shutterstock Smaller regulatory agencies